Anatara Lifesciences Limited Overview
| Field | Detail |
|---|---|
| Legal name | Anatara Lifesciences Ltd |
| ABN | 41 145 239 872 |
| Former names | None recorded (Market Index lists no former company names) |
| Incorporation date | 15 July 2010 (IBISWorld enterprise profile, citing ASIC registration) |
| Incorporation jurisdiction | Australia; for-profit company limited by shares, incorporated and domiciled in Australia (FY2026 financial report, Note 1) |
| Registered office and principal place of business | c/- Perks, Level 8, 81 Flinders Street, Adelaide SA 5000, Australia (FY2026 corporate directory) |
| Historical base | Brisbane, Queensland, at IPO and through roughly 2020. Registered office later moved to Adelaide. |
| Exchange and ticker | Australian Securities Exchange (ASX: ANR); sole listing |
| Other quoted securities | Listed options (7 cent exercise price, expiry 11 December 2025) lapsed unexercised on 11 December 2025. No other quoted securities remain. |
| ISIN | AU000000ANR0 |
| CUSIP | Not applicable; no US listing |
| Fiscal year end | 30 June |
| IPO | October 2014; raised A$7 million at A$0.50 per share. Listing date reported as 16 October 2014 by Pearler. The financialfilings.com summary states December 2014, which conflicts. |
| Subsidiary | Sarantis Pty Ltd (Australia, 100%, dormant) |
| Auditor | Grant Thornton Audit Pty Ltd, Adelaide; lead partner J L Humphrey |
| Share registry | Computershare Investor Services Pty Ltd, Brisbane |
| Solicitors | Thomson Geer, Brisbane |
| Bankers | Commonwealth Bank of Australia |
| Website | www.anataralifesciences.com |
| Shares on issue | 315,950,765 ordinary shares at 30 June 2026. A small further issue followed in August 2026 from conversion of performance rights (Appendix 2A, 24 August 2026). |
| Unquoted options | 10,500,000, with exercise prices of A$0.025 to A$0.10 (FY2026 directors' report) |
| Performance rights | 496,702 at the date of the FY2026 report |
| Last observed share price | About A$0.009 to A$0.010 (InvestSMART, August to September 2026). |
| Market capitalisation | About A$2.8 million to A$3.2 million (315.95m shares × A$0.009 to A$0.010). StockAnalysis showed A$3.16m on 16 July 2026. |
| Chief executive | No CEO. Dr David Brookes, Executive Chair, is the chief operating decision maker (FY2026 Note 5). |
The entity profiled is the same listed company named in the request. There has been no name change, delisting, or change of listing venue. Anatara Lifesciences Ltd remains quoted on the ASX under code ANR.
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Employee benefits expense excl. super (AUD k) | 687.6 | 695.6 | 660.2 | 551.7 |
| Superannuation expense (AUD k) | 74.9 | 65.9 | 71.7 | 53.8 |
| Total KMP remuneration (AUD k) | 786.9 | 716.3 | 685.0 | 444.4 |
| Executive KMP count at year end | 3 | 3 | 2 | 1 |
Anatara does not disclose headcount. The best available proxy is employee benefits expense plus the key management personnel (KMP) roster.
At 30 June 2026 the only executive KMP was the Executive Chair. Chief Development Officer Simon Erskine resigned on 13 May 2026. FY2026 annual leave provisions were A$8,375 and long service leave A$599, which points to a workforce of perhaps one to three salaried staff, supported by contractors. This is an inference; the company does not state a figure.
Anatara Lifesciences is an Adelaide-based, ASX-listed micro-cap biotech. It began as a bromelain-based animal health company built around Detach®, a non-antibiotic treatment for scour (diarrhoea) in piglets. Detach was licensed to Zoetis in 2018 and handed back in 2019. Anatara then repositioned toward human gastrointestinal health through GaRP (Gastrointestinal ReProgramming), a multi-component, multi-coated complementary medicine made from "Generally Regarded As Safe" (GRAS) ingredients. In April 2025, GaRP's Phase II trial in irritable bowel syndrome (IBS) missed its primary efficacy endpoint. The company has since run on austerity. It has explored an early-stage oral Anti-Obesity Project (compound "AOC"), aimed at limiting weight regain after patients stop GLP-1 drugs, while assessing corporate transactions. With cash of A$0.47 million at 30 June 2026, no product revenue, and a material-uncertainty going-concern opinion, Anatara is best characterised as a listed shell-like vehicle. Its value rests on residual GaRP IP, early anti-obesity data, A$14.2 million of carried-forward tax losses, and its ASX listing.
Company's own description (FY2026 Annual Report)
The FY2026 directors' report describes the group as an Australian listed entity that develops and commercialises innovative, evidence-based products for gastrointestinal health in areas of significant unmet need. It says the company is building a pipeline of human health products, with a particular focus on conditions involving the complexity of the gastrointestinal tract. The report states there was no significant change in principal activities during FY2026. The FY2025 annual report, released in October 2025, framed the strategy as using proprietary technology and strategic partnerships to build a pipeline of health products.
Independent characterisation
Anatara is a pre-revenue, single-segment development company. Its operating model is asset-light and virtual. It has no manufacturing, laboratories or clinical operations of its own. Pre-clinical work is outsourced to universities (most recently the University of Newcastle), clinical trials to contract sites, and formulation to contract manufacturers. Since the GaRP-IBS trial failed in April 2025, the business has three activities:
-
Asset monetisation. It is seeking to commercialise or license the GaRP IP and know-how. Manuscripts on the pre-clinical work and the trial have been submitted for publication.
-
Option-value R&D. It has run a modest (more than A$350,000) proof-of-concept programme on AOC. The programme was put on hold in the June 2026 quarter while other transactions were negotiated.
-
Corporate development. It is evaluating transactions in the junior healthcare sector.
The last activity is now arguably the dominant value driver. It positions Anatara as a potential vehicle for a merger, asset injection or reverse takeover.
Revenue model
| Revenue type | Status (FY2026) | Commentary |
|---|---|---|
| Product sales | — | GaRP was never commercialised. Detach was approved in Australia historically, but no sales are recorded in FY2023 to FY2026. |
| Services | — | Not applicable |
| Subscription | — | Not applicable |
| Licensing and royalties | None recognised | The Zoetis deal (2018–2019) produced up-front payments. Under its terms Anatara was to receive US$2.5m up-front, US$2m of which had been received by the time of Stockhead's coverage. No licensing income has been recorded in recent years. |
| Government incentives | 100% of FY2026 other income | Refundable Australian R&D Tax Incentive (R&DTI): A$318,402 in FY2026 and A$969,456 in FY2025 |
Value chain position
| Stage | Anatara role |
|---|---|
| Discovery and formulation | In-house IP (multi-component, multi-coated GaRP formulation; AOC candidate selection) |
| Pre-clinical | Outsourced (University of Newcastle for AOC; IBD mouse model work for GaRP) |
| Clinical | Sponsor of GaRP-IBS Phase II run through contract sites (5 sites across 3 Australian capital cities in Q4 FY2024) |
| Regulatory | Groundwork for listing on the Australian Register of Therapeutic Goods (TGA); regulatory framework work for the EU and US (FY2024 report) |
| Manufacturing | Contract manufacturers; scale-up and packaging work started in FY2024; stability above 24 months demonstrated |
| Commercialisation | Intended through out-licensing to pharma or consumer-health partners; no partner secured |
Customer types and end-markets
Anatara has no customers today. Its intended counterparties and end-markets are:
Global consumer health and pharma companies: seeking evidence-based complementary medicines for gut health, IBS and the gut–brain axis (GaRP licensing).
-
Weight-management and nutraceutical markets, especially adjunct or maintenance products for people stopping GLP-1 receptor agonists (AOC).
-
Animal health companies, historically, for Detach, BONIFF (piglet dry-feed formulation) and ANR-pf (poultry in-water formulation). The FY2023 half-year report said interest in the bromelain animal portfolio would be pursued through consultancy agreements.
Strategy
Stated strategy themes (FY2025–FY2026 annual reports, 2025 AGM)
| Theme (paraphrased from company disclosures) | Evidence |
|---|---|
| Build a pipeline of evidence-based human health products where unmet need is significant | FY2026 principal activities |
| Use proprietary technology and strategic partnerships | FY2025 annual report summary |
| Get the most value from the GaRP project after the IBS trial | Manuscripts submitted; commercial discussions; company says commercial interest in the GaRP IP remains |
| Advance the Anti-Obesity Project through proof of concept, then a Phase 1 PK study if justified | FY2026 review; project on hold in Q4 FY2026 |
| Evaluate other opportunities and strategic directions in the junior healthcare sector | FY2026 corporate activities; 4C reports Q2–Q4 FY2026 |
| Continuing austerity | 2025 AGM address; FY2026 capital management note says non-critical spending was cut |
Strategic initiatives in the last 24 months (Oct 2024–Oct 2026)
| Initiative | Timing | Status | Targets / spend |
|---|---|---|---|
| Anti-Obesity Project (AOC) | Launched about Nov 2024; mouse studies started about Apr 2025 at the University of Newcastle | Pre-clinical PoC done (Dec 2025 / Feb 2026); Phase 1 PK study designed and tendered; on hold in Q4 FY2026 | More than A$350,000 spent on PoC studies |
| GaRP-IBS Phase II Stage 2 completion | Recruitment paused Dec 2024; results Apr/May 2025 | Completed; primary endpoint missed; formally closed out in FY2026 | Main driver of FY2025's A$1.60m research spend |
| GaRP publication and commercial packaging | FY2026 | Pre-clinical and clinical manuscripts submitted for peer review (by Q4 FY2026) | Low cost |
| GaRP IP expansion | Jan–May 2025 | Australian and Hong Kong patents granted | — |
| GaRP IBD mouse-model pre-clinical work | Reported in Q4 FY2026 | Studies in an internationally recognised IBD mouse model | — |
| Board renewal and capital-markets capability | Sep 2025 | Van Dissel (ECM and M&A background) appointed | — |
| A$1.2m recapitalisation | Oct–Nov 2025 | Completed (100m shares at A$0.012) | Net A$1.1m |
| Corporate transaction evaluation | Ongoing; negotiations "progressed" in Q4 FY2026 | Undisclosed. No transaction announced as of the latest filings reviewed. | — |
| Cost programme | FY2025–FY2026 | G&A down 26%, research down 82%, investor relations down 91% in FY2026; CDO role not replaced | Implicit |
Sustainability and ESG commitments
None disclosed. The company states it is not subject to significant environmental regulation.
Medium-term financial targets and guidance
Anatara gives no financial guidance or medium-term targets. The only quantitative forward-looking statement is that its FY2026 R&DTI claim, lodged with AusIndustry on 28 July 2026, is expected to produce a rebate of more than A$300,000 (Q4 FY2026 4C). The accrued receivable is A$316,996.
Products & Services
All products sit in the single reported segment. They are grouped below by therapeutic franchise.
Human health
| Product / programme | Description | Key specifications and capabilities | Target customer | Stage / latest milestone | Pricing |
|---|---|---|---|---|---|
| GaRP (Gastrointestinal ReProgramming); working name, branding refreshed in FY2024 | Multi-component, multi-coated oral complementary medicine | Made from GRAS components, including bromelain. Designed to help restore and maintain the GI lining and microbiome balance. Coatings target release in the ileum and colon. Shelf stability above 24 months in tested conditions (FY2024). | IBS and potentially IBD patients; gut–brain axis wellness; licensees in global consumer health | Phase II GaRP-IBS trial concluded. Primary efficacy endpoint missed (17 Apr 2025). Trial formally closed out in FY2026. Pre-clinical and clinical manuscripts submitted for peer review (Q4 FY2026). | Not disclosed; never commercialised |
| 3FDC (sub-formulation) | A 3-component subset of GaRP | Studied for effects of a dietary subset of GaRP components on psychological functioning in adults (FY2023 half-year report) | Gut–brain axis applications | Exploratory; current status not disclosed | — |
| AOC (Anti-Obesity Project candidate compound) | Oral complementary medicine or nutraceutical intended to help maintain weight loss and limit rebound after stopping GLP-1 agonists (e.g., semaglutide) | Intended mechanism: stimulating endogenous GLP-1. The compound is recognised as GRAS. In diet-induced obese mice, AOC significantly reduced weight regain after semaglutide was stopped (p<0.019) and reduced perigonadal (visceral) fat weight (n=12, p=0.024). MOA assays were inconclusive on a direct endogenous GLP-1 effect (19 Feb 2026). | Patients stopping or maintaining GLP-1 therapy; nutraceutical and consumer-health licensees | Pre-clinical proof of concept complete. A multidose Phase 1 pharmacokinetic study in healthy volunteers was designed and tenders sought in Australia and the EU. The project was put on hold in the June 2026 quarter. Q4 FY2026 commentary also mentions an open-label trial as an option. | Not applicable |
Animal health (legacy)
| Product | Description | Target | Status |
|---|---|---|---|
| Detach® | Bromelain-based, non-antibiotic oral treatment for scour (diarrhoea) in piglets. Bromelain is a pineapple-stem enzyme extract that blocks gut receptor sites used by pathogens to attach. | Pig producers; animal health majors | Historically approved in Australia. Licensed to Zoetis May 2018, returned June 2019. No sales or active development disclosed in FY2024–FY2026. Still named in the segment description. |
| BONIFF | Revised Detach formulation applied to dry feed for piglets after weaning; reduces labour input | Pig producers | Development status not disclosed since about 2022 |
| ANR-pf | Proprietary enriched formulation for poultry delivered in drinking water; quick, flexible dosing | Poultry producers | Development status not disclosed since about 2022 |
Services
None. The FY2024 report mentioned ongoing discussions on possible uses of Anatara's existing products and know-how in animal health. FY2023 commentary pointed to consultancy-style monetisation, but no consultancy income has been reported.
Financial Narrative
Sources: FY2026 Financial Report (FY2026 and FY2025 figures); FY2024 Financial Report (FY2024 and FY2023 figures, plus FY2022 closing balances from comparatives and the statement of changes in equity); 5-year remuneration report tables (FY2022 net loss and EPS). FY2022 total assets and operating cash flow come from an aggregator (Kalkine) and are flagged in the notes.
Income statement
Notes:
-
FY2022 net loss and EPS come from the 5-year table in the FY2024 and FY2026 remuneration reports.
-
FY2023 "other grants and income" combines A$24,600 of grants and a A$6,096 lease modification gain.
-
EBITDA is computed as operating loss plus depreciation. It is an analyst calculation.
-
The remuneration reports give earlier losses of A$1.996m (FY2021) and A$3.365m (FY2020).
Margins and growth
Gross, operating, EBITDA and net margins are not meaningful because there is no revenue from customers. Revenue CAGR (FY2022–FY2026) is also not meaningful (zero product revenue throughout). The CAGR of other income from FY2023 to FY2026 is -36.5% per year (analyst calculation).
Balance sheet
Notes:
-
FY2022 equity, issued capital, reserves and accumulated losses are the 1 July 2022 opening balances in the FY2024 statement of changes in equity.
-
FY2022 cash is the 1 July 2022 opening balance in the FY2024 cash flow statement.
-
Negative net debt means net cash.
Cash flow
Notes:
-
FY2022 net change in cash is derived from Kalkine's FY2021 cash of A$3.43m less the filed FY2022 closing cash of A$1.12m.
-
FY2024 investing inflow of A$50k came from term deposit proceeds.
Ratios (analyst calculations from filed figures)
Notes:
-
FY2023 ROA uses the FY2022 aggregator total assets figure.
-
ROIC is approximated as operating loss after nil tax divided by average equity plus debt.
-
Net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful (negative EBITDA, no revenue, no inventory).
-
The FY2025 ROA of -138.7% matches the -138.64% published by FNArena, which cross-checks the calculation method.
-
The FY2026 runway figure is flattering. The year's A$0.34m operating outflow was cut by the A$0.97m FY2025 R&DTI refund received in July 2025. Gross payments to suppliers and employees were A$1.31m. Q3 and Q4 FY2026 operating outflows were A$0.327m and A$0.286m per quarter, which implies a real runway of roughly 4 to 5 quarters from A$0.47m plus an expected R&DTI refund of more than A$0.3m.
Commentary on trends, inflections and drivers
Loss trajectory. The net loss fell from A$2.53m in FY2022 to A$0.93m in FY2026, but not in a straight line. FY2025 bucked the trend: the loss rose 34.7% to A$1.95m because research spending doubled to A$1.60m to finish Stage 2 of the GaRP-IBS trial and start the anti-obesity pre-clinical work. FY2026 is the clearest inflection. Research spending collapsed 82.5% to A$0.28m after the trial was formally closed and staff cut to essential roles. G&A fell 26.4% to A$0.97m, mostly from lower employee costs (down A$108k) and investor relations (down A$125k, or 91%). The FY2026 loss reflects retrenchment, not commercial progress.
R&DTI dependency. The refundable R&DTI is the only source of "income." It also works as a quasi-financing tool: in April 2025 Anatara borrowed A$400k at 11% against the expected refund. Because the incentive tracks eligible R&D spending, the FY2026 cut in research mechanically shrinks next year's refund (FY2026 receivable A$317k vs A$970k a year earlier). Austerity therefore saves less than headline research figures suggest.
Capital structure and dilution. Shares on issue have risen about 4.4 times in four years (71.4m to 316.0m). Issue prices fell from A$0.035 (FY2023) to A$0.022 (Dec 2023), then recovered to A$0.04–A$0.05 (May–Dec 2024) on Stage 1 optimism, before falling to A$0.012 (Oct 2025) after the trial failure. Cumulative issued capital of A$25.3m against accumulated losses of A$24.8m leaves equity of only A$0.71m. The balance sheet has no debt and no intangibles; it is essentially cash plus the R&DTI receivable.
Liquidity cycle. Year-end cash has swung widely (A$0.35m in FY2023, A$0.98m in FY2024, A$0.10m in FY2025, A$0.47m in FY2026). This reflects a recurring cycle: raise equity in the December half, collect the R&DTI around August, run cash down toward June. The FY2025 low of A$0.10m, with a A$0.41m loan outstanding, was the company's most precarious point. The auditor has included a material-uncertainty paragraph on going concern in each of FY2024, FY2025 and FY2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue from customers (AUD K) | 0 | 0 | 0 |
Segment other income, mainly R&DTI (AUD K) | 644.0 | 969.5 | 318.4 |
Segment operating loss (AUD K) | -1,459.1 | -1,956.6 | -935.1 |
Segment pre-tax loss (AUD K) | -1,451.2 | -1,954.7 | -933.2 |
YoY change in pre-tax loss (%) | -28.3 | 34.7 | -52.3 |
Share of group income (%) | 100 | 100 | 100 |
Group Entities
| Entity | Jurisdiction | Ownership | Status |
|---|---|---|---|
Anatara Lifesciences Ltd | Australia | Listed parent | Operating parent; holds all IP and activities |
Sarantis Pty Ltd | Australia | 100% | Dormant (FY2026 Note 24) |
Function Details
| Function | Holder | Status at 7 Oct 2026 |
|---|---|---|
Executive Chair / CODM | Dr David Brookes | In role |
Chief Development Officer | Simon Erskine | Resigned 13 May 2026; not replaced (no announcement located) |
Chief Scientific Officer | Dr Michael West | Re-appointed Mar 2024. Status after the GaRP close-out in FY2026 is not disclosed; he is not listed as KMP. |
Company Secretary | Jonathan Lindh | In role since 29 Nov 2024 |
CFO | No CFO disclosed. The directors' declaration refers to CEO/CFO declarations, but no such named officers appear in the FY2026 report. | — |
“—” = not publicly disclosed.
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from customers (AUD K) | — | 0 | 0 | 0 | 0 |
Other income total (AUD K) | — | 1,245.8 | 644.0 | 969.5 | 318.4 |
R&D tax incentive income (AUD K) | — | 1,215.2 | 626.1 | 969.5 | 318.4 |
Other grants and income (AUD K) | — | 30.7 | 17.9 | 0 | 0 |
General and administrative expenses (AUD K) | — | -1,682.7 | -1,354.2 | -1,322.7 | -973.0 |
Research expenses (AUD K) | — | -1,602.2 | -748.9 | -1,603.4 | -280.5 |
Operating loss / EBIT (AUD K) | — | -2,039.1 | -1,459.1 | -1,956.6 | -935.1 |
Depreciation (AUD K) | — | 24.8 | 2.5 | 0.7 | 0.1 |
EBITDA (AUD K) | — | -2,014.3 | -1,456.7 | -1,955.9 | -935.0 |
Net finance income (AUD K) | — | 15.9 | 7.9 | 1.9 | 1.9 |
Pre-tax loss (AUD K) | -2,532.3 | -2,023.2 | -1,451.2 | -1,954.7 | -933.2 |
Income tax (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net loss (AUD K) | -2,532.3 | -2,023.2 | -1,451.2 | -1,954.7 | -933.2 |
Basic EPS (AUD cents) | -3.56 | -2.07 | -0.97 | -0.95 | -0.34 |
Diluted EPS (AUD cents) | -3.56 | -2.07 | -0.97 | -0.95 | -0.34 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
Weighted avg shares (millions) | — | 97.9 | 150.0 | 204.7 | 277.9 |
Shares on issue at year end (millions) | 71.36 | 119.92 | 191.14 | 213.38 | 315.95 |
Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
R&D share of operating expenses (%) | 48.8 | 35.6 | 54.8 | 22.4 |
Other income cover of operating expenses (%) | 37.9 | 30.6 | 33.1 | 25.4 |
YoY change in net loss (%) | -20.1 | -28.3 | 34.7 | -52.3 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD K) | 1,120.2 | 351.2 | 982.1 | 101.4 | 470.9 |
Trade and other receivables (AUD K) | — | 1,004.1 | 671.1 | 1,028.3 | 334.7 |
of which R&DTI receivable (AUD K) | — | 923.2 | 626.1 | 970.2 | 317.0 |
Total current assets (AUD K) | 1,700 | 1,416.1 | 1,670.6 | 1,148.3 | 820.4 |
Total assets (AUD K) | 1,770 | 1,419.4 | 1,671.4 | 1,148.4 | 820.4 |
Goodwill and intangibles (AUD K) | 0 | 0 | 0 | 0 | 0 |
Short-term borrowings (AUD K) | — | 0 | 0 | 407.4 | 0 |
Long-term borrowings (AUD K) | — | 0 | 0 | 0 | 0 |
Total debt (AUD K) | — | 0 | 0 | 407.4 | 0 |
Net debt (AUD K) | — | -351.2 | -982.1 | 306.1 | -470.9 |
Total current liabilities (AUD K) | — | 494.2 | 304.2 | 607.2 | 108.3 |
Total liabilities (AUD K) | — | 494.8 | 306.8 | 612.4 | 108.9 |
Working capital (AUD K) | — | 921.9 | 1,366.5 | 541.1 | 712.1 |
Issued capital (AUD K) | 19,908.5 | 21,368.7 | 23,176.6 | 24,146.9 | 25,323.4 |
Reserves (AUD K) | 439.5 | 347.7 | 278.0 | 416.9 | 171.9 |
Accumulated losses (AUD K) | -18,983.7 | -20,791.9 | -22,090.1 | -24,027.8 | -24,783.8 |
Total equity (AUD K) | 1,364.3 | 924.5 | 1,364.6 | 536.0 | 711.5 |
NTA per share (AUD cents) | — | 0.71 | 0.77 | 0.25 | 0.23 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Payments to suppliers and employees (AUD K) | — | -3,072.0 | -2,195.8 | -2,906.0 | -1,305.3 |
R&DTI and grants received (AUD K) | — | 771.9 | 923.2 | 624.6 | 971.6 |
Operating cash flow (AUD K) | -2,232.9 | -2,257.9 | -1,247.4 | -2,272.0 | -339.2 |
Capex (AUD K) | — | -1.7 | 0 | 0 | 0 |
Free cash flow (AUD K) | — | -2,259.6 | -1,247.4 | -2,272.0 | -339.2 |
Gross equity raised (AUD K) | — | 1,697.5 | 1,985.3 | 1,094.5 | 1,200.0 |
Share issue costs paid (AUD K) | — | -188.7 | -157.0 | -103.3 | -91.2 |
Net borrowings (AUD K) | — | 0 | 0 | 400.0 | -400.0 |
Net financing cash flow (AUD K) | -22.4 | 1,490.6 | 1,828.3 | 1,391.2 | 708.8 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD K) | -2,309.8 | -769.0 | 630.9 | -880.8 | 369.6 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
ROE on average equity (%) | -176.8 | -126.8 | -205.7 | -149.6 |
ROA on average total assets (%) | -126.9 | -93.9 | -138.7 | -94.8 |
ROIC (%) | -176.8 | -126.8 | -163.3 | -149.6 |
Current ratio (x) | 2.87 | 5.49 | 1.89 | 7.58 |
Debt to equity (x) | 0 | 0 | 0.76 | 0 |
Cash runway at that year's operating burn (months) | 1.9 | 9.4 | 0.5 | 16.7 |
Key Financials
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Unused tax losses, no DTA recognised (AUD K) | 11,609.6 | 12,625.5 | 13,466.9 | 14,186.0 |
Potential tax benefit at 25% (AUD K) | 2,902.4 | 3,156.4 | 3,366.7 | 3,546.5 |
Share-based payment expense (AUD K) | 54.6 | 28.6 | 106.0 | 32.0 |
Investor relations expense (AUD K) | 71.3 | 103.5 | 137.2 | 12.1 |
Accounting and audit fees (AUD K) | 207.0 | 184.9 | 166.8 | 169.1 |
D&O insurance premium (AUD K) | — | 30.3 | — | 30.0 |
Results by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia other income (AUD K) | 644.0 | 969.5 | 318.4 |
Americas income (AUD K) | 0 | 0 | 0 |
EMEA income (AUD K) | 0 | 0 | 0 |
APAC excluding Australia income (AUD K) | 0 | 0 | 0 |
Jurisdiction Details
| Jurisdiction | Relevance |
|---|---|
Australia | GaRP patent granted (Jan 2025); trial sites; TGA listing groundwork |
Hong Kong | GaRP patent granted (May 2025) |
EU, Japan, Korea, other APAC | GaRP patent family applications prosecuted (FY2024 report); EU tenders sought for the AOC Phase 1 study (FY2026) |
United States | FDA GRAS confirmation for bromelain (2017); historical Zoetis partnership |
Share Price
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Share price at 30 June (AUD) | 1.26 | 1.00 | 0.635 | 0.255 | 0.13 | 0.155 | 0.055 | 0.028 | 0.042 | 0.008 | 0.01 |
Share Price & Returns
| Period | Return | Basis |
|---|---|---|
1-year | About +25% if the A$0.008 estimate is used; -80% if the filed A$0.05 is used | 30 Jun 2025 to 30 Jun 2026 at A$0.01; result depends on the disputed FY2025 figure |
3-year | -64% | A$0.028 (Jun 2023) to A$0.01 (Jun 2026) |
5-year | -94% | A$0.155 (Jun 2021) to A$0.01 (Jun 2026) |
Since IPO | -98% | A$0.50 IPO price to about A$0.009–A$0.010 |
52-week range (to Jul 2026) | A$0.005 to A$0.020 | StockAnalysis |
Valuation Snapshot
| Metric | Value | Comment |
|---|---|---|
Market capitalisation | About A$2.84m | 315.95m shares |
Fully diluted shares | About 326.9m | Adds 10.5m options (all out of the money at A$0.025–A$0.10) and 0.50m performance rights |
Enterprise value | About A$2.37m | Market cap less A$0.471m cash, no debt (30 Jun 2026 basis) |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | No sales |
P/B | About 4.0x | Book equity A$0.712m |
Price / NTA per share | About 3.9x | NTA 0.23 cents per share (FY2026 Appendix 4E) |
Peer comparison | n/m | Pre-revenue ASX micro-cap biotechs are usually valued on cash, pipeline optionality and listing ("shell") value, not earnings multiples |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None. StockAnalysis lists no analyst targets. Simply Wall St reports 2 nominal covering analysts with no submitted estimates. Historical sponsored research came from Pitt Street Research (2019). |
Dividends | Never declared since inception. Franking account nil. Dividend policy: none until profitable. |
Credit ratings (Moody's, S&P, Fitch) | Not rated |
Debt maturity profile | No debt at 30 June 2026. The only recent borrowing (A$400k RTL loan, Apr–Aug 2025) has been repaid. |
Share Price & Returns by Date
| Date | Type | Price (AUD) | Shares (m) | Gross (AUD K) |
|---|---|---|---|---|
Oct 2022–Feb 2023 | Placement, entitlement and shortfall (with 1-for-2 options at 7c) | 0.035 | 48.5 | 1,697.5 |
Dec 2023 | 2-for-5 entitlement | 0.022 | 48.0 | 1,055.3 |
May 2024 | Placement | 0.040 | 23.25 | 930.0 |
Jul 2024 | Director placement | 0.040 | 1.75 | 70.0 |
Nov–Dec 2024 | Placements | 0.050 | 20.49 | 1,024.5 |
Oct–Nov 2025 | Two-tranche placement | 0.012 | 100.0 | 1,200.0 |
Analyst Conclusions
Management guidance
There is no revenue or earnings guidance. Disclosed near-term expectations:
-
An R&DTI rebate of more than A$300k from the FY2026 claim (lodged 28 Jul 2026, expected to be processed from August).
-
Peer-reviewed publication of GaRP pre-clinical and clinical papers.
-
Continued evaluation of transactions in the junior healthcare sector.
-
AOC to progress only if resources and strategic direction allow (currently on hold).
Consensus expectations
None exist. No broker consensus is available.
Bull case
-
Transaction optionality. Management says negotiations on other transactions progressed in Q4 FY2026. With an enterprise value of about A$2.4m, a debt-free balance sheet, A$14.2m of tax losses and an ASX listing, even a modest asset injection or merger could re-rate the shares from deeply depressed levels (P/NTA about 3.9x on a tiny base).
-
Residual GaRP value. Significant pain, frequency and distension benefits, an anxiety signal, granted AU and HK patents, and pending peer-reviewed papers could support an out-licence to a consumer-health company, where the evidence bar is lower than for prescription drugs.
-
AOC targets a large, recognised need. Rebound after stopping GLP-1 drugs is clinically documented. AOC's statistically significant mouse data (p<0.019 on regain; p=0.024 on visceral fat) and GRAS status could justify a cheap Phase 1 PK study and partnering interest.
Bear case
-
Funding treadmill. Cash of A$0.471m, three straight going-concern warnings and gross spending of about A$1.3m a year mean further discounted raises are likely. Shares on issue have already risen 4.4 times since FY2022.
-
Pipeline credibility. GaRP failed its primary endpoint. AOC's MOA data were inconclusive on its own mechanism, and the programme is on hold. There is no clinical-stage asset with a validated efficacy path.
-
Thin governance and execution capacity. A three-person board without a clearly independent majority, no CEO or CFO, and the CDO's departure leave execution resting on one executive. Any transaction may be heavily dilutive to existing holders and could forfeit the tax losses.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| FY2026 Annual Report (top-20 holders, substantial holders) | About 16 Oct 2026 | Ownership clarity; possible strategy update |
| FY2026 R&DTI refund receipt (more than A$300k) | Q2 FY2027 (Oct–Dec 2026) | Extends runway by about 1 quarter |
| 2026 AGM (likely Nov 2026) | Nov 2026 | Board re-election, placement capacity resolutions, strategy |
| Q1 FY2027 Appendix 4C | By 31 Oct 2026 | Burn rate and any transaction update |
| Announcement of any transaction (asset acquisition, merger, RTO) | Unknown | Main value driver; check for trading halts |
| GaRP manuscript acceptance or publication | 6–12 months | Supports licensing discussions |
| GaRP licence or term sheet | Unknown | Would validate residual asset value |
| AOC Phase 1 PK study decision | Unknown (on hold) | Restart would signal confidence and funding |
| Capital raising terms | Likely H1 FY2027 | Dilution and price signal |
| ASX compliance commentary on level of operations | Ongoing | Suspension or delisting tail risk |
Analyst verdict
Anatara Lifesciences is no longer a conventional development-stage biotech. It is a listed vehicle in transition. Its decade-long bet on bromelain-based gastrointestinal products has produced one approved animal product (Detach), one licence that ended (Zoetis, 2018–2019) and one Phase II human trial that met safety but missed its primary efficacy endpoint (GaRP-IBS, April 2025). Since then the board has cut spending sharply: FY2026 research fell 82% to A$0.28m and the net loss halved to A$0.93m. That bought time, not traction. With A$0.471m of cash, no revenue, equity of A$0.71m and a third consecutive going-concern warning, the company's fate depends on what it does next, not on its existing pipeline.
Two assets are worth more than the market assigns. The first is the GaRP data package and patents. Properly published, they could support a modest consumer-health licence built on the pain, distension and anxiety findings rather than the failed composite endpoint. The second is the corporate shell: debt-free, with A$14.2m of tax losses and a board recently strengthened with capital-markets and M&A experience. The explicit reference to progressing transaction negotiations, and the decision to shelve AOC while they continue, suggests that a corporate event is the main near-term catalyst.
Against that, AOC's inconclusive mechanism data, the lack of any partner, a tiny executive team and the near-certainty of further dilutive funding argue strongly for caution. At an enterprise value of about A$2.4m, the shares are effectively an option on a transaction. The size of the payoff depends on terms that are not yet disclosed. For institutional purposes, Anatara is unsuitable for fundamental ownership until a transaction is announced. It is a monitor-only special situation. The decisive monitorables are the FY2026 annual report's register disclosure, the 2026 AGM resolutions and any trading halt announcing a deal.
APPENDIX: SOURCES
1: Anatara Lifesciences, Appendix 4E & Financial Report for the year ended 30 June 2026 (lodged 18 Aug 2026; via Webull bulletin mirror) — FY2025–FY2026 financials, directors, remuneration, operations, capital, notes
2: Anatara Lifesciences, Appendix 4E & Financial Report for the year ended 30 June 2024 (ASX, 22 Aug 2024) — FY2023–FY2024 financials, FY2022 opening balances, 5-year loss table, history
3: Q1 FY2026 Appendix 4C activities report (23 Oct 2025) — AOC progress, GaRP commercial status
4: 2025 AGM Executive Chair's address (20 Nov 2025) — Strategy, placebo-response commentary
5: InvestSMART summaries of the Q2 FY2026 (30 Jan 2026), Q3 FY2026 (29 Apr 2026) and FY2026 4E announcements — Quarterly cash, announcement log
6: Kalkine Media (31 Jul 2026) and InvestorPA summaries of the Q4 FY2026 4C — June 2026 quarter cash, R&DTI claim
7: Biotech Dispatch (Apr 2025 articles) — GaRP-IBS readout, AOC study start
8: SmallCaps (2024 articles) — Stage 2 trial design and recruitment
9: TipRanks company announcement summaries (2025) — Market cap snapshots, board and funding events
10: Biotech Daily, Dr Boreham's Crucible (30 Aug 2019); Stockhead; FNArena / Pitt Street Research (Jul 2019); FNN interview with S. Lydeamore — Corporate history, Zoetis deal, IPO
11: Business Wire / BioSpace (Zoetis option agreement release) — Zoetis partnership
12: Market Index (ANR page) — Year-end share price history, director trades
13: StockAnalysis (ASX: ANR) — Market cap, 52-week range, shares out
14: Simply Wall St (ownership page) — Insider transactions, ownership mix (aggregator)
15: Kalkine company page (ASX: ANR) — FY2022 total assets and operating cash flow (aggregator)
16: IBISWorld enterprise profile — Incorporation date
17: financialfilings.com; Zonebourse news log — ISIN, filing chronology
18: Pearler — Product descriptions (BONIFF, ANR-pf), IPO date
19: Sperber et al., Gastroenterology (2021); WHO / NCD-RisC (Lancet, 2024); Wilding et al., Diabetes, Obesity and Metabolism (2022) — Industry context (general knowledge; not re-retrieved in this session)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background and prior roles | Education | Other listed boards |
|---|---|---|---|---|---|
Dr David Brookes | Executive Chair. Member of the audit and risk committee and the remuneration and nominations committee. | Director since at least Dec 2020; Executive Chair through FY2023–FY2026 | Biotech analyst from the late 1990s. Former Chairman of genomics company RHS Ltd (acquired by PerkinElmer in June 2018). Former Non-Executive Chairman of Better Medical Group (sold to Livingbridge, Jan 2021). Practising clinician and biotech consultant. | MBBS (Adelaide); Fellow, Australian College of Rural and Remote Medicine; Fellow, AICD | Current: TALI Digital (ASX:TD1) since 29 Jun 2020, as Executive Director. Former: Island Pharmaceuticals (ASX:ILA), Oct 2020–19 Sep 2024; Dominion Minerals (ASX:DLM, formerly Factor Therapeutics), 10 Apr 2019–16 Jun 2025. |
Mr John Michailidis | Non-Executive Director. Chaired the audit and risk committee to Sep 2025. | COO before Oct 2023; Executive Director 2 Oct 2023–17 Apr 2025; NED since 17 Apr 2025 | More than 30 years as a CEO in healthcare, pharma and biotech in Australia and overseas. Experience in business transformation, translational science commercialisation and government engagement. | — | — |
Mr Dirk van Dissel | Non-Executive Director. Chair of the audit and risk committee; member of the remuneration and nomination committee. | Appointed 29 Sep 2025 (the remuneration report says 28 Sep 2025, a minor inconsistency) | More than 20 years in private equity, boutique investment banking and stockbroking. Focus on corporate advisory and equity capital markets for micro- and small-caps in life sciences, tech and resources. Experienced in assessing early-stage healthcare projects and in buy- and sell-side M&A. | — | — |
“—” = not publicly disclosed.
Board of Directors — Sue MacLeman
| Name | Role | Exit date | Context |
|---|---|---|---|
Sue MacLeman | — | 7 Dec 2022 | Board renewal during the FY2023 recapitalisation |
Dr Jane Ryan | Non-Executive Director; chaired the remuneration committee | 2 Oct 2023 | Retired. Also a director of Bionomics and IDT Australia. |
Nicholas Haslam | Non-Executive Director; chaired the audit committee | 28 Feb 2025 | Resigned ahead of the trial readout |
Stephen Denaro | Company Secretary (since 24 Feb 2014) | 29 Nov 2024 | Retired |
Jonathan Lindh | Interim Non-Executive Director | 29 Sep 2025 | Stepped down when van Dissel joined; stays Company Secretary |
Simon Erskine | Chief Development Officer | 13 May 2026 | Resigned; performance rights fully converted to shares before departure |
Steven Lydeamore | CEO (Zoetis/pivot era, about 2018–2020) | — | Leadership moved to an Executive Chair model |
Dr Tracey Mynott | Co-inventor of Detach; former CSO | — | Founder-era scientist |
Dr Mel Bridges | Former Chairman (Zoetis option era) | — | Historical |
Directors' Remuneration
| Name | Salary / fees | Superannuation | Long service leave | Options | Performance rights | Total |
|---|---|---|---|---|---|---|
Dr David Brookes (Executive Chair) | 150,000 | 18,000 | 0 | 0 | 0 | 168,000 |
Mr John Michailidis (NED) | 60,000 | 7,200 | 0 | 0 | 0 | 67,200 |
Mr Dirk van Dissel (NED, from 28/29 Sep 2025) | 50,400 | 0 | 0 | 0 | 0 | 50,400 |
Mr Jonathan Lindh (NED, to 28/29 Sep 2025) | 7,500 | 900 | 0 | 0 | 0 | 8,400 |
Mr Simon Erskine (CDO, to 13 May 2026) | 138,416 | 16,892 | -4,893 | 0 | 0 | 150,415 |
Total KMP | 406,316 | 42,992 | -4,893 | 0 | 0 | 444,415 |
Executive Leadership Team
| Name | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
David Brookes total (AUD) | 197,867 | 172,911 | 209,750 | 168,000 |
John Michailidis total (AUD) | 118,788 | 170,785 | 185,349 | 67,200 |
Simon Erskine total (AUD) | 313,822 | 289,400 | 216,924 | 150,415 |
Total KMP (AUD) | 786,869 | 716,346 | 684,988 | 444,415 |
Directors' Remuneration — Executive Chair contract
| Item | Detail |
|---|---|
Executive Chair contract | A$150,000 per year plus 12% superannuation; duration and notice unspecified |
Former CDO contract | A$160,000 per year plus 12% super in FY2026, down from A$220,000 including super in FY2024; 3 months' notice. STI up to 30% of fixed remuneration. |
Base fees | Chair A$150,000; other NEDs A$60,000 (excluding super) |
Aggregate NED fee pool | A$500,000 (set at IPO in Oct 2014) |
LTI plan | Executive Option Plan, approved at the AGM on 26 Nov 2020; service-based vesting |
Say-on-pay | About 99% in favour at the 2025 AGM (FY2025 report); more than 97% at the 2023 AGM |
Governance Overview
| Attribute | Assessment |
|---|---|
Board size | 3 directors |
Chair/CEO separation | No. There is no CEO; the Chair is executive and acts as CODM. |
Independence | At most 1 of 3 directors is clearly independent by conventional ASX standards. Brookes is executive. Michailidis was an executive until April 2025, which falls inside the ASX Principles' 3-year look-back. Van Dissel's related entity is paid for services, which needs a materiality assessment. |
Committees | Audit and Risk Management Committee (chair van Dissel; members Brookes, Michailidis); Remuneration and Nominations Committee (members Brookes, Michailidis, van Dissel). The remuneration report says this committee is "mainly comprised of independent non-executive directors." |
Meetings FY2026 | 11 board meetings, 2 audit, 1 remuneration; full attendance by all eligible directors |
Gender diversity | 0% female directors since Dr Jane Ryan left in Oct 2023 |
Governance framework | Reports against the ASX Corporate Governance Council Principles (4th edition) |
Major Shareholders
| Holder | Shares | % of 315.95m |
|---|---|---|
Dr David Brookes | 9,863,336 | 3.12 |
Mr Dirk van Dissel | 6,060,696 | 1.92 |
Mr John Michailidis | 1,299,999 | 0.41 |
Total KMP | 17,224,031 | 5.45 |
Governance Overview — Thorney Technologies Ltd
| Indicator | Detail | Source / date |
|---|---|---|
Thorney Technologies Ltd | On-market purchase of 939,142 shares (about A$42k) on 22 Nov 2024. | Simply Wall St |
RTL Investment Group | Lender of the A$400k R&DTI advance (Apr 2025). TipRanks described it as a major shareholder group. | FY2026 Note 11; TipRanks |
Ownership mix (May 2025, about 213m shares) | VC/PE 12.7%; institutions 13.3%; individual insiders 13.8%; private companies 14.8%; general public 45.4%; top 22 holders about 54.6% | Simply Wall St (aggregator) |
Competitive Landscape
Key Competitors
| # | Competitor | Programme overlap | Approx. scale (latest FY) | Positioning vs Anatara |
|---|---|---|---|---|
| 1 | Ironwood Pharmaceuticals (NASDAQ: IRWD) | IBS-C (linaclotide/Linzess, with AbbVie) | — | Approved prescription standard of care; Anatara has no approved IBS claim |
| 2 | AbbVie (NYSE: ABBV) | IBS-C (Linzess US partner), IBS-D (eluxadoline/Viberzi via Allergan) | About US$56bn group revenue (2024) | Big-pharma incumbent and potential licensee class |
| 3 | Bausch Health / Salix (NYSE: BHC) | IBS-D (rifaximin/Xifaxan) | — | Antibiotic approach vs Anatara's non-antibiotic GRAS approach |
| 4 | Ardelyx (NASDAQ: ARDX) | IBS-C (tenapanor/Ibsrela) | — | Newer prescription entrant |
| 5 | Microba Life Sciences (ASX: MAP) | Microbiome testing and therapeutics, including IBD | — | ASX microbiome peer, better capitalised |
| 6 | Immuron (ASX: IMC) | GI health (Travelan and Protectyn, gut-targeted complementary products) | — | ASX GI complementary-medicine peer with marketed products |
| 7 | Consumer probiotic and IBS supplement brands (e.g., Symprove, Align/P&G, IBgard/Bausch) | OTC IBS symptom relief | — | Low-evidence-bar competitors in the channel GaRP would target |
| 8 | Novo Nordisk (CPH: NOVO-B) | GLP-1 obesity drugs (Wegovy) | About DKK 290bn revenue (2024) | Defines the market AOC aims to complement |
| 9 | Eli Lilly (NYSE: LLY) | GLP-1/GIP obesity drugs (Zepbound); oral orforglipron in development | About US$45bn revenue (2024) | Oral incretins could reduce the need for maintenance adjuncts |
| 10 | Pendulum Therapeutics (private) | "GLP-1 Probiotic" consumer product | — | Direct nutraceutical analogue to AOC's endogenous GLP-1 concept |
| 11 | Zoetis (NYSE: ZTS) and Elanco (NYSE: ELAN) | Animal GI health (historical Detach market) | Zoetis about US$9.3bn (2024) | Former partner and incumbents in the legacy market |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Anatara (FY2026) | Ironwood (2024) | Ardelyx (2024) | Immuron (FY2025) |
|---|---|---|---|---|
Revenue | A$0 (other income A$0.32m) | About US$0.35bn | About US$0.33bn | — |
Revenue growth | n/m | — | — | — |
Profitability | Net loss A$0.93m | — | — | — |
R&D intensity | 22% of opex; n/m vs revenue | — | — | — |
Approved products | — | Yes (Linzess) | Yes (Ibsrela, Xphozah) | Yes (Travelan, OTC/listed medicine) |
Recent Developments
There were no layoff announcements as such, but headcount fell through the CDO resignation and the FY2026 cut to essential roles. No guidance was revised because none is given.



